ring finger protein 167Genealiases: 5730408C10Rik · LP2254 · RING105
Q-omics provides the consensus-scored RNF167 profile across patient tissues and cancer cell-line models. RNF167 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, RNF167 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, RNF167 protein abundance shows 20,386 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight PAAD, KICH, and LUAD as cancer lineages where RNF167 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF167 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF167 survival associations across molecular data types. RNF167 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF167 RNA expression–survival associations across cancer types. High RNF167 expression shows unfavorable associations in KICH, ACC, LUAD and LGG, but favorable associations in PAAD and KIRC. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for RNF167 RNA expression.
This table summarizes RNF167 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 8. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RNF167. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF167 shows lower tumor expression in KICH and THCA and higher tumor expression in KIRP, LIHC, BRCA and HNSC. The KICH box plot shows higher RNF167 RNA expression in normal versus tumor tissue (log2 FC = −1.168, t-test p < 0.001).
This table shows molecular features associated with RNF167 in patient tissues and cancer cell lines. In patient samples, RNF167 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF167 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LIVER and UPPER_AERODIGESTIVE_TRACT.
